MoMs Hips a Grinding Dilemma for Hospitals, Doctors, FDA
As health providers focused on the Supreme Court's ruling last week, a quieter but much more human drama about medical harm and suffering—and what federal policymakers should do about it—was unfolding inside a hotel just beyond the Maryland beltway.
For two days, a parade of orthopedic surgeons, biomedical device reps, safety experts, poison specialists, risk managers, lawyers, and patients appeared before a U.S. Food and Drug Administration panel to talk about the disastrous problems, questions, and fear surrounding MoMs.
MoMs, or metal-on-metal hip replacement or hip resurfacing systems, represent between 27% and 40% of the estimated 500,000 hip surgeries performed a year in the U.S., an industry valued at about $12 billion a year in 2009, although new procedures are apparently in decline.
Presumably, after this meeting, the FDA's 18-member Orthopaedic and Rehabilitation Devices Panel is thinking about what to do to clarify the safety of these devices. Should they recommend suspension of all further MoM implants as many patients and physicians recommend? And how should they further inform fearful patients who as yet have no symptoms what they should do in the meantime?
- Primary Care Docs Average More Hospital Revenue Than Specialists
- 69% of Employers Plan to Offer Healthcare Coverage After 2014
- How Chargemaster Data May Affect Hospital Revenue
- Q&A: Catholic Health Initiatives' New Senior VP for Capital Finance
- Building a Better Healthcare Board
- ED Physicians Key to Half of Hospital Admissions
- Hospital Pricing Irks Nurses; More Jobs, Less Pay
- Insurer's App Aims to Lower Healthcare Costs, Securely
- CMS Seeks to 'Rapidly Reduce' Medicare Spending with $1B in Grants
- Quiet ORs Better for Patient Safety